X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian share markets slip further 
(Mon, 7 Apr 01:30 pm) 
 
With persistent selling in index heavyweights, Indian share markets drifted deeper in the red in the post-noon trading session. All the sectoral indices are trading in the red with realty, consumer durable and power stocks being the biggest losers.

BSE-Sensex is down 112 points and NSE-Nifty is trading 28 points down. BSE Mid Cap is trading 0.7% down and BSE Small Cap index is trading down by 0.3%. The rupee is trading at 60.0 to the US dollar.

Most of the energy stocks are trading in the red with Indian Oil Corporation (IOC) and Petronet LNG being the major gainers whereas Cairn India and Gas Authority of India Ltd (GAIL) are trading in the red. As per a leading financial daily, ONGC Videsh, subsidiary of ONGC, is in talks to import Liquified Natural Gas (LNG) for $15 per unit from a consortium operating a giant gas field in Mozambique. ONGC Videsh Ltd (OVL) has a 16% stake in the Rovuma Area-1 project of the consortium whereas Oil India and Bharat Petroleum Corporation Ltd together hold 14% stake. OVL had recently acquired 10% stake in Mozambique's Rovum Area-1 together with Oil India which holds 4% stake. The company later bought an additional 10% stake in the same field from Anadarko Petroleum Corporation. The total amount of $ 4.12 bn spent on the acquisitions was financed through borrowings by the company. ONGC stock is currently trading up marginally.

Majority of the domestic pharma stocks are trading in the red with Cipla and Cadila Healthcare being among major losers while Glenmark Phrama and Elder Pharma are among the few stocks trading in the green. As per a leading financial daily, Dr. Reddy's Laboratories (DRL) will be investing $400 m in Research & Development over the next 3-4 years. The company generates a major portion of its revenues from pure generic sales and wants to shift focus on manufacturing complex generic drugs using science & technology. DRL is planning to invest $150-$200 m in each of the biologics and proprietary product segments. The company expects to derive a significant part of its revenues from these two product segments over the next five years. DRL has 21 active products in the proprietary products pipeline out of which six are in the clinical development stage in the areas of cardiovascular development, psoriasis, pain, anti-infective atopic dermatitis/psoariasis and migraine as on 31st March 2013. DRL's stock is currently trading down 1.4%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian share markets slip further". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE OIL & GAS


Sep 25, 2017 (Close)

S&P BSE OIL & GAS 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS